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Abstract
Background: Myocarditis is the major heart disease in infants and young adults. It is very commonly caused by
coxsackievirus B3 (CVB3) infection; however, no specific treatment or vaccine is available at present. RNA interference
(RNAi)-based anti-viral therapy has shown potential to inhibit viral replication, but this strategy faces two major challenges;
viral mutational escape from drug suppression and targeted delivery of the reagents to specific cell populations.
Methodology/Principal Findings: In this study, we designed artificial microRNAs (AmiRs) targeting the 39untranslated
region (39UTR) of CVB3 genome with mismatches to the central region of their targeting sites. Antiviral evaluation showed
that AmiR-1 and AmiR-2 reduced CVB3 (Kandolf and CG strains) replication approximately 100-fold in both HeLa cells and
HL-1 cardiomyoctes. To achieve specific delivery, we linked AmiRs to the folate-conjugated bacterial phage packaging RNA
(pRNA) and delivered the complexes into HeLa cells, a folate receptor positive cancer cells widely used as an in vitro model
for CVB3 infection, via folate-mediated specific internalization. We found that our designed pRNA-AmiRs conjugates were
tolerable to target mutations and have great potential to suppress viral mutational escape with little effect on triggering
interferon induction.
Conclusion/Significance: This study provides important clues for designing AmiRs targeting the 39UTR of viral genome. It
also proves the feasibility of specific deliver of AmiRs using conjugated pRNA vehicles. These small AmiRs combined with
pRNA-folate conjugates could form a promising system for antiviral drug development.
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Introduction
Myocarditis, the inflammation and injury of heart muscle cells,
causes up to 20% of all cases of sudden death in young adults [1].
Coxsackievirus B3 (CVB3) is the most prevalent cause of
myocarditis [2] but there is still no specific cure yet. RNA
interference (RNAi) has shown promising therapeutic potential
against chronic viral infections [3,4,5]. However, it is limited by
the fact that frequent mutations in the viral genome, especially the
RNA virus, compromise the effect of RNAi agents (6–8). Two of
the popular RNAi agents studied in anti-viral research are small
interfering RNAs (siRNAs) [6,7,8,9,10,11,12] and artificial micro-
RNAs (AmiRs) [5,13,14], the mimics of endogenous microRNAs
(miRNAs). siRNAs function by binding perfectly to the recognition
sites within viral genomic RNA or mRNA and cleaving those
molecules [15], while AmiRs usually partially bind to their targets
and destabilizing them or inhibit their translation. However, one
of the greatest challenges to develop specific and effective RNAi-
based antiviral therapy is that some viruses, especially RNA virus
like CVB3, possess a very high mutation rate [16,17,18,19].
siRNA treatment itself can also trigger vial mutations sometimes
[20,21,22]. Merl and others found that CVB3 can generate
mutants resistant to siRNA targeting [23]. Although targeting the
conserved region of viral genome [24] or treating the cells with a
combination of several siRNAs [23,25] can minimize the viral
escape, there are still viral mutants appeared and the viral titer
restored to relatively high level at 140 h post infection (pi) [23].
Different from siRNAs, AmiRs are expressed in the form of
primary miRNAs in the nucleus and cleaved by Drosha and
DGCR8 into the precursor miRNAs (pre-miRNAs), which are
transported into cytoplasm and further processed by Dicer into
,21-nt miRNA duplexes with two imperfect complementary
strands [26,27,28]. One, sometimes both of the two strands would
act as the mature miRNA incorporated into the RNA-induced
silencing complex (RISC). AmiRs target to, under most circum-
stances, the 39untranslated region (UTR) of selected mRNAs with
partial complementary sequences, resulting in the degradation or
translational inhibition of the targets [29]. Some of the AmiRs can
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miRNAs) with the targeting sites, making them better able to
tolerate mutations [30]. Though siRNA treatments against CVB3
infection have been tested in several studies
[10,23,24,25,31,32,33], there is still no report on using AmiRs to
inhibit CVB3 infection and replication. Considering that AmiRs
have better mutation tolerance to their targets and are less toxic
than traditional RNAi methods [34,35], it is worthwhile to design
AmiRs against CVB3.
The CVB3 genome encodes a single long open reading frame
flanked by a 59 and 39UTR [36]. The secondary structure of
CVB3 39UTR contains three stem-loops (Fig. 1A) [37]. The
interactions among these stem-loops enable the formation of
kissing-pair tertiary structure facilitating viral translation and
replication [37]. Some host cell proteins, such as La autoantigen in
HeLa cells, can bind to the 39UTR of CVB3, affecting viral
replication [38]. Our group designed antisense oligodeoxynucleo-
tides (AS-ODNs) targeting the 39UTR and inhibited the
translation and replication of CVB3 [39]. All of the evidence
supports the vital roles of the 39UTR in the replication of CVB3.
In addition, most endogenous miRNAs regulate gene expression
by targeting the 39UTR [29]. There have been studies using
AmiRs targeting the 39UTR of animal genes [40,41]. Liu and
coworkers designed AmiRs targeting the coding region of HIV
and they found these AmiRs also targeted the 39UTR of HIV
genome which was proved by luciferase assay [5]. However,
designing AmiRs targeting 39UTR viral genome is still a relatively
new strategy. Therefore, there is some prospect of developing
AmiRs to target the 39UTR of CVB3.
Another barrier to RNAi-based therapy is the non-specific
distribution of the drug in vivo after administration. Our group and
others have used a novel approach to deliver siRNA to inhibit viral
replication [42] or oncogenesis [43,44,45] with ligand-linked
bacterial phage packaging RNA (pRNA) as a vehicle, but this
method has not been tested on AmiRs. Discovered about two
decades ago within the bacteria phage 29, pRNA plays essential
roles in packaging the phage DNA [46] and has great potential to
deliver nucleic acid based drugs. pRNA monomers are also
capable of assembling dimmers, trimers and even hexamers
[47,48,49,50], which makes it possible to deliver drug combina-
tions conveniently. This multimerization may also enable the
pRNA to carry both therapeutic molecules and the ligand
simultaneously for targeted delivery. Previous studies have
demonstrated that the folate-conjugated pRNA is a powerful
vehicle to deliver siRNA molecules into the cancer cell lines
[42,43,44,45]. Folate is an essential extrinsic vitamin required by
most mammalian cells for nucleotide biosynthesis and thereby
important for DNA synthesis and repair. The folate receptor is one
of the receptors responsible for transport of folate and is highly
expressed in epithelial cells, macrophages and various tumor cells
like HeLa cells [51,52,53]. Thus folate is a promising ligand
candidate for the targeted drug delivery to cancer cells.
The main goal of this study was to design effective AmiRs with
mutation tolerance to inhibit CVB3 replication. Further, we
investigated the feasibility to deliver AmiRs using folate-linked
pRNA as a vehicle. These AmiRs linked with the pRNA were
delivered into the cells either by Oligofectamin
TM mediated
transfection or by folate mediated internalization and the antiviral
effect was evaluated. We report that AmiRs targeting the stem-
loop of the CVB3 39UTR are tolerable to target mutations and
effective in inhibiting replication of CVB3 with little effect on
interferon (IFN) induction. Therefore, the pRNA-ligand mediated
delivery strategy holds promise for more specific delivery of AmiRs
to treat viral infection.
Materials and Methods
Virus, cell culture, infection and transfection
CVB3 (Kandolf) was produced from a full-length cDNA clone
(provided by Reinhard Kandolf, University of Tubingen, Ger-
many) and CVB3 (CG strain) was provided by Charles J. Gauntt.
Viruses were stored at 280uC. HeLa cells (American Type
Culture Collection), the viral hosts, were cultured in a Dulbecco’s
modified Eagle’s medium (DMEM) (Lonza) supplemented with
10% fetal bovine serum (FBS) (Sigma) and 100 mg/ml of
penicillin-streptomycin (Invitrogen) in a 37uC incubator contain-
ing 5% CO2. HL-1 cells, a cardiomyocyte cell line as another cell
host, were obtained from Dr. William C. Claycomb. (Louisiana
State University Medical Center, New Orleans, LA) and
maintained as described previously [54]. Virus was amplified in
HeLa cells by infection. Virus titers were routinely determined at
the beginning of each experiment by plaque assay as described
later. For infection, 8610
5 cells were seeded to each well of a 6-
well plate. After incubation at 37uC for 20 h, cells were washed
with phosphate buffered saline (PBS) (Lonza) and infected with
CVB3 (Kandolf or CG) at a multiplicity of infection (MOI) of 0.01
or 10 for 60 min. Sham infection was conducted using supernatant
without CVB3 as a negative control. After infection, the cells were
washed with PBS, overlaid with 2 mL of DMEM containing 10%
FBS, and incubated for 24 h or 8 h at 37uC. Finally, the
supernatants from each treatment were collected by centrifugation
at 5,0006g for 5 min and kept at 280uC until use. The cell pellets
were re-suspended in a Modified Oncogen Science lysis buffer
(MOSLB) (50 mM NaPyrophosphate, 50 mM NaF, 50 mM
NaCl, 5 mM EDTA, 5 mM EGTA, 100 mM Na3VO4, 10 mM
HEPES, and 0.1%Triton X-100) and the cell lysates were stored at
220uC until use.
The transfection of pRNA-AmiRs was conducted by using
Oligofectamine
TM (Invitrogen) following the manufacturer’s
instructions with minor modifications. Briefly, HeLa cells or HL-
1 cells (3610
5) were seeded to each well of a 6-well plate for 24 h.
When cells reached approximately 50% confluence, they were
washed with PBS and incubated with 1 mL of transfection
complexes containing 3 mL of Oligofectamine
TM and 100 pmol
pRNA-AmiRs for 48 h. Mock transfection was conducted using
the Oligofectamine
TM without pRNA-AmiRs. Cells were then
infected with CVB3 (Kandolf or CG) as described above.
AmiR design
Three 21-nt AmiRs (AmiR-1, AmiR-2, AmiR-3) with one
nucleotide mismatches to their targets in the middle region (nt
11
th) were designed to target the 39UTR of CVB3 (Fig. 1A, 1B)
and one scrambled AmiR (AmiR-S) was used as a negative
control. For each AmiR, we also designed a partial complemen-
tary strand to form double-stranded AmiR duplexes containing
wobble base-pairing mimicking the endogenous miRNA duplexes
(Fig. 1C). All AmiRs were incorporated to a human hsa-miR-126
precursor backbone to form pre-AmiRs mimicking the in vivo pre-
miRNAs (Fig. 1C). Each pre-AmiR was synthesized along with the
59 and 39 end sequences containing restriction enzyme sites
BamHI and AflII, respectively. These segments were inserted into
a miRNA-expressing vector, pRNAT-CMV 3.1/Hygro (Gen-
script), which carries a cGFP (coral GFP) reporter gene. The
AmiR sequences were confirmed by sequencing.
Establishment of AmiR-expressing HeLa cell lines
AmiR-expressing HeLa cell lines, which can grow well in the
presence of 150 mg/mL hygromycin, were established by plasmid
transfection using the Lipofectamine
TM 2000 reagent following the
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PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21215Figure 1. Design of anti-CVB3 AmiRs A) AmiR targeting sites in the 39UTR of CVB3 genome. The secondary structure of 39UTR of CVB3
contains three stem-loops, X, Y and Z. Three AmiR candidates, AmiR-1 (blue), AmiR-2 (orange) and AmiR-3 (green), were designed to target the stem-
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(,1.5610
6) were seeded in each 60-mm culture dish. After
incubation for 20 h, the cells reached about 90% confluence and
were washed twice with PBS. A transfection mixture containing
8 mg of plasmid DNA and 20 mL of Lipofectamine
TM 2000 in
1 mL of Opti-MEMH (Invitrogen) was added to each dish and the
cells were incubated for 6 h at 37uC. The cells were then washed
with PBS and incubated with 4 ml of DMEM containing 10%
FBS at 37uC. After transfection for 24 h, cells were washed with
PBS, lifted from plates by Trypsin-EDTA (Gibco) and subcultured
to several 10-cm plates with 10 mL of DMEM containing 10%
FBS and 150 mg/mL hygromycin for each plate. The medium was
changed every 48 h. After about 2 weeks, the survived clones
appeared were passaged to a 24-well plate and checked under
fluorescent microscope (Nikon). The green ones were further
confirmed by Western blot detection for the expression of cGFP.
Preparation of pRNA-AmiRs
The pRNA-AmiR chimerics were produced by in vitro
transcription of cDNA fragments encoding the corresponding
pRNA-AmiRs. The cDNA fragments were amplified by PCR
using the primers listed in Table 1 and a pRNA A-b’ or pRNA B-
a’ plasmid kindly provided by Dr. Peixuan Guo [55] as templates.
The in vitro transcription was driven by the T7 phage 2.5 promoter
using T7-MEGAShortscript kit (Ambion) according to the
manufacturer’s instructions. 300 ng of the amplified cDNA
fragments were transcribed in a 40 mL reaction volume in the
presence of ATP, CTP, GTP and UTP (7.5 mM each) at 37uC for
4 h. The transcription products were then purified by 8% urea-
polyacrylamide gel electrophoresis (PAGE) in TBE buffer and
eluted with 0.5 M sodium acetate, 0.1 mM EDTA and 0.1%
sodium dodecyl sulfate (SDS). The eluted products were further
precipitated with ethanol and re-suspended in RNase free water.
Labeling of pRNA-AmiR chimerics with folate
Folate-labeled pRNA-AmiR chimerics were prepared as
previously described for labeling pRNA-siRNA [42,45]. 650 ng
(0.2 mM in final concentration) of cDNA fragments were
transcribed in 40 ml of reaction buffer containing 40 mM Tris
(pH 8.0), 6 mM MgCl2, 2 mM spermidine, 0.01% Triton X-100,
5 mM DTT, and 5 U/mL T7 RNA polymerase (Promega),
together with 4 mM folate-AMP (synthesized by TriLink Bio-
Technologies, USA), 0.25 mM ATP, 1 mM CTP, GTP and UTP.
The transcription products were then purified by 8% urea-PAGE,
eluted with 0.5 M sodium acetate, 0.1 mM EDTA and 0.1% SDS
and analyzed by separation through an 8% urea-PAGE in TBE
buffer. About 1 mg RNA in gel loading buffer II (Ambion) was
heated at 95uC for 5 min and then loaded onto the gels. Gels were
run at 140 V for 2–2.5 h and then stained in TBE buffer
containing 36Gel Read (Biotium).
Folate-pRNA-AmiR heterodimer formation
Folate-labeled pRNA-AmiR heterodimers were prepared by
mixing folate-pRNA-Ba’ and pRNA-Ab’ (AmiR-1), or pRNA-Ab’
(AmiR-2), or pRNA-Ab’ (AmiR-S) which are based on a pRNA
(A-b’) structure in a 1:1 molar ratio (0.2 mM each) in a total
volume of 200 mL solution containing 10 mM MgCl2,5mLo f
RNAse OUT RNase inhibitor (Invitrogen), 15 mL of 0.1 mM
DTT and 20 mLo f1 0 6 RT buffer (Invitrogen) and then
incubated at 37uC for 1 h. The pRNA heterodimers were
analyzed by native PAGE in TBM buffer as described previously
[56].
Delivery of folate labeled pRNA-AmiR monomers or
heterodimers into HeLa cells
HeLa cells were maintained in folate-free RPMI 1640 medium
(Gibco) for two weeks and 8610
5 cells/well were then plated into a
6-well plate one day before the experiment. Cells were then
washed with PBS containing 10 mM MgCl2 and incubated with
0.5 nmol of folate-labeled pRNA-AmiR monomers or heterodi-
mers in 1 mL of binding solution (serum free RPMI medium
containing 10 mM MgCl2, and 1 U/mL SUPERRNase inhibitor
(Ambion)) for 8 h at 37uC. After incubation, free RNA was
removed by washing with PBS. Mock treatment using the same
Table 1. Primers used for producing pRNA-AmiR chimerics and luciferase reporter constructs.
DNA Primer Sequences (59R39)*
pRNA vector Forward: TAATACGACTCACTATTAGGGTACGGTACTTCCATTGTCATGTGTATGTTGGGGATTA
Reverse: TGCACTTTTGCCATGATTGACGGACAATCAAC
pRNA-miRNA1 Forward: TAATACGACTCACTATTAACCGAACCAACTAATGCGTACATTTGTATGTTGGGGATTA
Reverse: ACCGAACCAACTAACGGTACAAAATTGACACGCAATCAAC
pRNA-miRNA2 Forward: TAATACGACTCACTATTATGTGCTAACCTAGCAGTGATAATTTGTATGTTGGGGATTA
Reverse: TGTGCTAACCTAACCAGATAAAAATTGACACGCAATCAAC
pRNA-miRNAS Forward: TAATACGACTCACTATTAGACCCCGGTTTACGTGTGGGTCTTTGTATGTTGGGGATTA
Reverse: GACCCCGGTTTACGTGGGGTCAAATTGACACGCAATCAAC
Wt-CVB3-3UTR Forward: GCCGGTTTAAACGACAATTTG
Reverse: GCGCGTCTAGATTTTTTTTTTCC
*The T7 promoter regions are underlined and the restriction enzyme sites are italicized.
doi:10.1371/journal.pone.0021215.t001
loop Y, the biggest stem-loop. B) The predicted complementation between AmiRs and their target sequences. The prediction was
conducted by using Sfold software. The total target mirWIP scores are indicated. A mismatch was designed in the middle of the target. C)
Secondary structures of pre-AmiRs. All the AmiRs were inserted to the hsa-mir-126 scaffold to form pre-miRNAs. The sequences circled by the
green box are backbones of miR-126; sense and antisense strand of AmiR sequences were labeled. The mismatch regions between the two strands
were marked with red box.
doi:10.1371/journal.pone.0021215.g001
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Cells were then infected with CVB3 (Kandolf) at 0.01 MOI for
20 h. Cell lysates and supernatants were collected for Western blot
and viral plaque assay to evaluate the CVB3 replication as
described below.
Quantitative reverse-transcriptional PCR (q-RT-PCR)
Total RNAs from AmiR-expressing cell lines or pRNA-AmiR
transfected cells were isolated using miRNeasy Mini Kit (Qiagen).
The RNAs were then analyzed by q-RT-PCR using Custom
TaqMan Small RNA Assay reagents (Applied Biosystems, Assay
ID : pRNA-AmiR-1: CSY9XW6; pRNA-AmiR-2: CS0IV3E)
based on the stem-loop RT-PCR technology, which only measures
the mature form of AmiRs [57]. An U6 snRNA measurement
using TaqMan Assay served as an endogenous control.
Cell viability assay
Cell viability was measured by using a 3-(4,5-dimethylthiazol-
2-yl) -5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium salt (MTS) assay kit (Promega) according to the
manufacturer’s instructions. Cells were incubated with MTS
solution for 2 h, and the absorbance was measured at 492 nm
using an enzyme-linked immunosorbent assay (ELISA) reader
(SLT Lab Instruments). The survival values for absorbance of
sham-infected cells were defined as 100%, and the remaining
infected data, including that for AmiR-expressing cells, pRNA-
AmiR transfected cells, folate-pRNA-AmiR monomer or dim-
mer treated cells and mock-transfected cells, was converted to
the ratio of the sham-infected sample. Morphological changes of
cells following CVB3 infection were evaluated by phase-contrast
microscopy.
Western blotting analysis
Protein concentration for each sample was quantified by the
Bradford assay using fat-free-bovine serum albumin (BSA) as the
standard. Western blotting was performed by standard protocols
as previously described [39]. Briefly, equal amounts of proteins
were subjected to sodium dodecyl sulfate (SDS)-PAGE and then
transferred to nitrocellulose membranes (Pall Corporation). The
membranes were blocked with 5% skim milk in TBST buffer
(25 mM Tris-HCl, 137 mM NaCl, 0.1% (v/v) Tween-20, pH 7.6)
for 1 h and probed with primary monoclonal mouse antibodies
against CVB3 capsid protein VP-1 (DAKO), beta actin (Sigma), or
caspase-3 (Santa Cruz) or a primary rabbit polyclonal antibody
against GFP (Invitrogen) overnight at 4uC, followed by wash with
TBST for three times and incubation with horseradish-peroxidase-
conjugated goat secondary antibody to anti-mouse immunoglob-
ulin G or to anti-rabbit immunoglobulin G (1:2000 dilution, Santa
Cruz) for 90 min at room temperature. The signals were detected
by ECL reagents (Syngene).
Viral plaque assay
The virus titer was determined by plaque assay as described
previously [58]. Briefly, HeLa cells (8610
5 cells/well) were seeded
into 6-well plates and incubated at 37uC for 20 h. When cell
confluence reached approximately 90%, cells were washed with
PBS and then overlaid with 800 ml of diluted supernatants
containing viral particles. The cells were incubated at 37uC for
60 min, and the supernatants were removed. Finally, cells were
washed with PBS again and overlaid with 2 ml of sterilized soft
Bacto-agar-minimal essential medium (0.75% Agar). The cells
were incubated at 37uC for 72 h, fixed with Carnoy’s fixative for
30 min, and then stained with 1% crystal violet. The plaques were
counted, and the virus titer was calculated as the plaque forming
units per ml (pfu/mL).
Luciferase reporter assay
Wild type (wt) CVB3 39UTR (nt 7306–7399 GenBank:
M88483.1) was cloned from a previous CVB3 39UTR clone
[38] by PCR using primers including the restriction enzyme sites
listed in Table 1. The mutant (mut) CVB3 39UTRs (Mut-Y1 and
Mut-Y2) containing the restriction enzyme sites were synthesized
using miniGENES synthesis service from Integrated DNA
Technologies. Each 39UTR fragments (wt or mut) was inserted
at the PmeI and XbaI restriction sties into the pmirGLO Dual-
Luciferase miRNA Target Expression Vector (Promega) which co-
expresses firefly and Renilla luciferases. For luciferase reporter
assay, HeLa cells (2610
4/well) were plated in 96-well plates for
24 h and then co-transfected with the constructed luciferase
reporter plasmids (wt or mut, 100 ng/well) and the pRNA-AmiR
chimerics (2 pmol/well) using Lipofectamine
TM 2000 (Invitrogen).
Cells co-transfected with pRNA-AmiR chimerics and the
pmirGLO empty vector or only transfected with a reporter
plasmid vector were used as controls. Two days post transfection,
firefly and Renilla luciferase activities were detected on an ELISA
reader (TECAN) using the Dual-Glo luciferase analysis system
(Promega) according to the manufacturer’s protocol. The relative
luciferase activity was calculated using the ratio of firefly to Renilla
and then normalized to the pmir-GLO control group which was
set as 1.0.
Interferon (IFN) induction analysis
Total RNAs from HeLa cells transfected with AmiR-expression
vectors or pRNA-AmiR were collected using miRNeasy Mini Kit
(Qiagen). The RNAs were reverse transcribed to cDNA using
SuperScriptH III First-Strand Synthesis System (Invitrogen). The
gene markers for interferon induction including IFITM1, ISGF3-
gamma, OAS1 and OAS2 were detected using the Interferon
Response Detection Kit (System Biosciences) by q-PCR and
normalized to beta-actin following the manufacturer’s instructions.
The Oligofectamine
TM transfected HeLa cells were used to serve
as a negative control, and the positive control (cDNA from IFN
treated cells) was provided by the kit.
Statistical analysis
Statistical significance was evaluated using the Student t-test for
paired comparisons. All values are expressed as means 6 SD. A p-
value of ,0.05 was considered statistically significant.
Results
Design of AmiR sequences targeting the 39UTR of CVB3
The 39UTR is an essential region of CVB3 genome for its
replication [37,38] and most endogenous miRNAs exert their
inhibitory effect by binding the 39UTR of the target mRNAs
[59]. These reports led us to design three AmiRs targeting the
CVB3 39UTR (Fig. 1A). Among the three (X, Y and Z) loop
structures of CVB3 39UTR, Y loop was selected for AmiR
targeting (AmiR-1 targeting nt 7349–7369 and AmiR-2 targeting
nt 7342–7362) for the following two reasons; First, the interaction
between loop X and Y was shown to be critical for CVB3
replication [37]; Secondly, being the largest loop structure, Y
loop may provide more space to allow the AmiRs to bind to the
single strand region more easily. An on-line prediction tool
STarMir (http://sfold.wadsworth.org/starmir.pl) was used to
screen potential AmiRs targeting the different regions of CVB3
39UTR and those targeting the Y loop region scored the highest
Targeted Delivery of Anti-CVB3 Artificial MicroRNA
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close to the Y loop (AmiR-3 targeting nt 7359–7379) for
comparisons and one scrambled AmiR (AmiR-S) as a negative
control.
In order to mimic the endogenous miRNA strucrure, we
introduced mismatches between the designed AmiRs and their
potential targets. All the mismatches were located in the middle
region of the AmiRs to follow the general miRNA targeting
principles published previously [30,60,61]: i) the 59 end regions of
miRNAs (nt 2-7 or -8), named as the seeding region, are
mandatory to be complementary to the targets, ii) the presence
of highly complementary sequences in the 39 end region of
miRNAs improves the specificity of miRNAs and iii) the miRNAs
with mismatches to their targets in the central region (nt 9–11) are
more likely to be effective than the ones with mismatches in other
regions. A partial complementary strand was also designed for
each AmiR to form a double-stranded molecule (miRNA duplex)
similar to natural miRNAs (Fig. 1C). In order to mimic the in vivo
process of miRNA, the AmiRs were incorporated into a natural
miRNA precursor backbone. Previous studies have shown that
both animal and plant miRNA precursors can be modified to
express small RNAs with sequences unrelated to the original
miRNA produced by the precursors [62,63]. In our study, we used
human hsa-mir-126 precursor (Fig. 1C), which has been proved to
be effective for AmiR construction [64], for AmiR expression in
HeLa cell lines.
Inhibition of CVB3 replication by AmiRs
To test if our designed AmiRs could inhibit CVB3 replication,
HeLa cell lines expressing these individual AmiRs were
established by transfection of the cells with the constructed
AmiR expressing plasmids. Positive cell colonies were confirmed
by fluorescent microscopy and Western blot detection of cGFP
expression (Fig. 2A and 2B). The different cell lines were
subsequently infected with CVB3 (Kandolf) and the antiviral
effect of the AmiRs was evaluated by observation of cell
morphologies and measurement of cell viabilities. As shown in
Fig. 2C, more than 80% of AmiR-1 expressing cells were still
alive after 24 h infection. The anti-CVB3 activity was followed by
AmiR-2 (more than 70% cell survival). However, AmiR-3 did not
show significant protection of the cell against CVB3 infection
compared with AmiR-S control. The result of MTS assay was
consistent with the morphological observation (Fig. 2D). To
investigate the impact of AmiRs on CVB3 gene translation, we
determined the expression levels of CVB3 VP-1 by Western blot.
Fig. 3A shows that the VP-1 levels were significantly lower in the
AmiR-1 (0.55) and AmiR-2 (0.70) cells than in the control (1.00).
However, AmiR-3 did not show significant inhibition of CVB3
VP1 synthesis. The antiviral effect of these AmiRs was further
validated by viral plaque assay. Our results confirmed that AmiR-
1 and AmiR-2 reduced the viral particle numbers by approxi-
mately 1.5 log10 and 1.2 log10, respectively; whereas AmiR-3 did
not lower the viral replication as compared with the AmiR-S
control group (Fig. 3B).
To confirm that the antiviral effects of AmiR-1 and AmiR-2
were due to the expression of mature AmiRs in the established cell
lines, we conducted q-RT-PCR to measure the expression levels of
mature AmiR-1 and AmiR-2 and demonstrated an over 300-fold
increase of these mature AmiRs in the corresponding cell lines as
compared to the AmiR-S control (Fig. 3C). As expected, the
AmiR-1 or AmiR-2 level was undetectable in the AmiR-S cell line.
This demonstrated that the designed AmiRs were properly
processed into mature and functional forms in the cells.
pRNA-AmiRs chimerics can be processed into mature
functional AmiRs
In order to improve the targeted delivery of the AmiRs, the
designed AmiRs were linked to the pRNA vehicle by in vitro
transcription of pRNA plasmid DNA (Fig. 4A) [55] using primers
listed in Table 1. The produced RNA transcripts containing, in
order, the sense AmiR sequence, a 59 poly-A linker, the pRNA
vector sequence (nt29–91), a 39poly-A linker and the anti-sense
AmiR sequence. The secondary structure of the pRNA-AmiR is
shown in Fig. 4B. The three AmiR sequences listed in the lower
panel were used to replace the helical region of the pRNA as
indicated in the box. These chimeric transcripts were purified with
urea-polyacrylamide gel running in TBE buffer (Fig. 4C). A
pRNA-Vec (nt 29–91 of original pRNA sequence) was prepared as
a negative control.
To ensure that the AmiRs had been properly processed into
mature form after delivery to the cells, we performed q-RT-PCR
to detect the mature AmiR levels in the pRNA-AmiR transfected
HeLa cells. Fig. 4D shows that the mature AmiR-1 and AmiR-2
levels were dramatically increased in the pRNA-AmiR-1 and
pRNA-AmiR-2 transfected cells, respectively, compared with the
pRNA-AmiR-S treated cells. This indicates that the AmiRs were
properly processed in the cells.
To determine whether AmiRs still had anti-CVB3 activity after
processing from the pRNA vector, we observed cell morphology
and measured viral protein synthesis as well as viral particle release
in the pRNA-AmiR transfected HeLa cells. Meanwhile, to confirm
the anti-CVB3 effectiveness of the pRNA-AmiR in different CVB3
strains, we infected the cells using two viral strains (Kandolf and
CG), respectively. We also used high and low viral titers (10 and
0.01 MOI) to determine the inhibitory effect of pRNA-AmiRs on
cells infected for both long and short terms. Both cell morphologies
and MTS cell viability assay showed that pRNA-AmiR-1 and
pRNA-AmiR-2 effectively prevented the cells from death caused
by CVB3 (Kandolf) infection. During the high titers of viral
infection (10 MOI), as shown in Fig. 5A,and 5B, the living cells in
plates treated with pRNA-AmiR-1 and pRNA-AmiR-2 at 8 h post
infection were 80% and 70%, respectively; while only approxi-
mately 40% cells survived in other groups. The CVB3-induced
caspase-3 cleavage, a widely used marker for cell apoptosis, was
dramatically attenuated by the treatment of pRNA-AmiR-1 or
pRNA-AmiR-2 (Fig. 5C). The antiviral effects of these AmiRs
were further validated by Western blot analysis of VP-1 protein
and plaque assay of the CVB3 particle formation. The data
showed that substantial inhibition of VP-1 expression (Fig. 5D)
and an approximately 1.5 log10 reduction of viral particle numbers
(Fig. 5E) were observed in pRNA-AmiR-1 and pRNA-AmiR-2
transfected cells, respectively, as compared with the scrambled
pRNA-AmiR-S, pRNA-Vec, and mock-tranfected controls. These
results were more significant when infected the cells with a lower
CVB3 titer (0.01 MOI). As shown in Fig. 6, an over 50% increase
in cell survival, approximately 90% (pRNA-AmiR-1) or 60%
(pRNA-AmiR-2) decrease in VP1 production and a 2-log10
reduction of viral progeny release were observed as compared to
the control groups. The antiviral effect of the pRNA-AmiR was
further confirmed by using another strain of CVB3 (CG) as shown
in Fig. 7. To further determine the therapeutic potential of the
pRNA-AmiR, we also perform the evaluation using HL-1 cells, a
mouse cardiomyocyte cell line which is more closely related to the
in vivo myocarditis model of CVB3 infection in heart. As shown in
Fig. 8 and Fig. 9, the pRNA-AmiR-1 and pRNA-AmiR-2 in both
viral strains were also able to decrease CVB3 induced cell death
and inhibit CVB3 replication with about 1.5 log10 reduction of
viral progeny release. In general, the antiviral effect of AmiRs was
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21215Figure 2. AmiRs inhibit CVB3 induced cell death in AmiR-expressing cell lines. A) Establishment of AmiR-expressing cell lines. Four
stable cell lines over-expressing an individual AmiR were established by transfection of HeLa cells with the AmiR plasmids. cGFP tag expression was
used as a selection marker. B) Western Blotting analysis for cGFP expression of the established AmiR cell lines. The cell lysates of these cell
lines were collected and applied to Western blotting detection of cGFP expression. The non-transfected HeLa cell lysate served as a negative control.
C) Cell morphology changes after CVB3 infection. Cell lines expressing different AmiRs were infected with CVB3 (Kandolf). Cell morphology
was observed under a phase-contrast microscope. Dying cells appeared rounding and detachment. D) MTS assay of CVB3 infected AmiR cells.
Cell lines expressing different AmiRs were infected with CVB3 as described above. Cell viability was measured by MTS assay. The survival values of the
samples were converted to the ratio of the sham-infected HeLa cells, which were defined as 100%.
doi:10.1371/journal.pone.0021215.g002
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21215Figure 3. AmiRs inhibit CVB3 replication in AmiR-expressing cell lines. A) Western blotting detection of CVB3 VP-1 protein. Different
AmiR cell lines were infected with CVB3 (Kandolf) and cell lysates were collected for VP-1 detection by Western blotting. Sham infected cells served as
a negative control. The VP-1 expression levels were quantified by densitometry and normalized to the level of beta-actin. The ratios of VP-1 to beta-
actin were further converted to the ratios of the value of AmiR-S cells, which was set as 1.0. B) Viral plaque assay. Cells were infected with CVB3 at
0.01 MOI for 24 h. The supernatant was collected to perform viral plaque assay to determine the viral titer. The upper panel is the representative viral
plaques for each cell line and the lower panel is the calculation of viral titers. C) q-RT-PCR detection of mature AmiRs. Total RNAs from the AmiR-1,
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PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21215well preserved after linking to a pRNA, and the AmiRs were
properly processed to functional miRNAs after delivery.
Targeted delivery of pRNA-AmiRs chimerics via folate and
its receptor interactions
pRNA has been employed to successful delivery siRNA to target
cells [42,44,45,65] by linking to a folate ligand. Effective binding
and internalization of folate conjugated pRNA has been
demonstrated by previous studies in our lab [42]. To determine
whether folate-labeled pRNA (F-pRNA) was also applicable for
AmiRs delivery, we conjugated folate to our pRNA-AmiR
chimerics and incubated them with folate starved HeLa cells. In
addition, since pRNA molecules are able to form dimers through
the interaction of left- and right-hand loops [47,48,49], we also
assembled the folate labeled pRNA-Vec and pRNA-AmiR
chimerics together to form pRNA dimers. In order to construct
the dimers, a pRNA (Ba’) (nt 7–109) molecule with a left-hand
loop a’ (39 C85C84U83G82) and a right-hand loop B (59
A45C46G47C48) was conjugated to folate. Because all the pRNA-
AmiR chimerics were designed based on the pRNA (Ab’) vector
which contained a right-hand loop A (59 G45G46A47C48) and a
left-hand loop b’ (39 U84G83C82G81), these chimerics can interact
to the pRNA Ba’ vector complementarily and form dimers
(Fig. 10A). The folate-labeled pRNA-AmiR chimerics were
analyzed by denaturing urea-PAGE and the heterodimers were
confirmed by native PAGE in TBM buffer (Fig. 10B, and 10C).
We constructed two monomers (F-pRNA-Ba’ and F-pRNA-
Ab’(AmiR-1)) and three heterodimers (F-pRNA-Ba’/pRNA-
Ab’(AmiR-1), F-pRNA-Ba’/pRNA-Ab’(AmiR-2) and F-pRNA-
Ba’/pRNA-Ab’(AmiR-S)) for this study.
To evaluate the antiviral effect of pRNA-AmiR chimerics
delivered through folate-mediated internalization, we incubated
(rather than transfected) the F-pRNA-Ab’(AmiR) monomers and
heterodimers with HeLa cells for 8 h and then infected the cells
with CVB3 for 20 h. Here we did not use HL-1cells as they can
not be cultured in RPMI medium. We used three control groups
to monitor the effectiveness and specificity of the chimerics: i) F-
pRNA-Ba’/pRNA-Ab’(AmiR-S) control for the vector and non-
specific AmiR sequences, ii) non-labeled pRNA-AmiR-1, control
for the specificity of delivery via folate internalization and iii) the
mock treated cells (binding solutions without any chimerics), a
fundamental negative control. The cell morphologies and MTS
assay indicated that more viable cells were present in culture
treated with F-pRNA-Ab’(AmiR-1) (69%), F-pRNA-Ba’/pRNA-
Ab’(AmiR-1) (71%) and F-pRNA-Ba’/pRNA-Ab’(AmiR-2) (69%)
than all the control groups (around 40%) (Fig. 11A and 11B). In
addition, Western blot showed that CVB3 VP1 synthesis was
suppressed in F-pRNA-Ab’(AmiR-1) (0.3), F-pRNA-Ba’/pRNA-
Ab’(AmiR-1) (0.4) and F-pRNA-Ba’/pRNA-Ab’(AmiR-2) (0.5)
(Fig. 11C). Plauqe assay also showed about 1.3 log10 reduction of
viral release in the three groups above (Fig. 11D). These results
suggest that folate-mediated delivery of pRNA-AmiR is a powerful
system for targeted delivery of therapeutic RNA molecules.
pRNA-AmiRs targeting the 39UTR of CVB3 tolerate
mutations of the target
To test whether our pRNA-AmiRs could specifically target the
39UTR of CVB3 RNA and their ability to tolerate mutations
within the targets, we constructed luciferase reporters harboring
either wt or mutated 39UTR of the CVB3 genome. Because the
secondary structure of the mRNA 39UTR can affect the miRNA
targeting [66], we inserted almost the whole CVB3 39UTR
sequence (nt 7306–nt 7399) instead of merely the target sites. To
test whether the location of mutation would affect the outcome of
targeting, two mutations were created. The first one (Mut-Y1) had
two point mutations at nt 7352–7353, which complement to the 39
region of AmiR-1 and the middle region of the AmiR-2,
respectively. The second one (Mut-Y2) introduced two point
mutations at nt 7359 to 7360, which are complementary to the
middle region of AmiR-1 and the 59 end region of AmiR-2,
respectively (Fig. 12A and 12B). The luciferase reporter constructs
were then co-transfected with pRNA-AmiR-1, pRNA-AmiR-2 or
pRNA-AmiR-S. Luciferase activity measurements showed that
both AmiR-1 and AmiR-2 could target the wt 39UTR of CVB3
and reduced the reporter gene expression compared with pmir-
GLO vector-only control, although AmiR-2 showed much lower
inhibitory effect (30%) than AmiR-1 (65%) (Fig. 12C). When
comparing the mutants, it was found that AmiR-1 still showed
45% and 50% inhibitory effect when targeting mutated sites at
59end region (Mut-Y1) or middle region (Mut-Y2) of the AmiR-1
target sequence, respectively, though they were lower than the wt
39UTR (65%, p,0.05). However, for AmiR-2, mutation at the 39
end region (Mut-Y2) of the target (complementary to the seed
sequence of miRNA) almost completely abolished the inhibitory
effect; whereas, mutation at the middle region (Mut-Y1) of AmiR-
2 target did not abolished the inhibitory effect of AmiR-2 (still
achieved 20% inhibitory effect, but lower than wt 39UTR (30%,
p,0.05)). As expected, pRNA-AmiR-S did not show any targeting
effect on the CVB3 39UTR (Fig. 12C). These results suggest that
AmiRs could regulate the gene expression in a similar manner as
endogenous miRNAs and could preserve its inhibitory activity
when a mutation occurs at the non-seed-match region of target
sequences.
The designed AmiRs and pRNA-AmiRs have little effect
on IFN induction
As one major concern of RNAi-based anti-viral therapy is the
side effect caused by IFN induction after delivery of exogenous
short RNAs [67,68], we tested the IFN induction by the AmiR
vectors and pRNA-AmiR transfection using IFN response
detection kit. As showed in Fig. 13, AmiR-expressing vectors did
not induce upregulation of any markers for IFN response and
pRNA-AmiR transfection only lead to minimal increase in
IFITM1 and ISGF3-gamma but showed no effect on induction
of OAS1 and OAS2. These results indicate that the designed
AmiR and pRNA-AmiR have very limited effect on IFN induction
and may be good candidates for developing anti-CVB3 drugs.
Discussion
One of the major limitations in RNAi-based viral inhibition is
the viral escape due to target mutations. In this study, we designed
artificial miRNAs targeting the 39UTR of CVB3 genome, a
crucial region for the viral replication, to inhibit CVB infection
[37,38]. By partially complementary targeting the 39UTR, the
AmiRs achieved promising anti-viral effect. This mode of action
also resembles the natural miRNAs by imperfectly matching the
AmiR-2 and AmiR-S cell lines were extracted. The expression of mature AmiR-1 and AmiR-2 were measured by q-RT-PCR and normalized to the
expression of U6 RNAin each sample. Therelative mature AmiR-1 andAmiR-2levelsin the AmiR-Scell line were setas 0. Thevalues shownrepresentthe
means 6 SD of the data from three independent experiments, P,0.05.
doi:10.1371/journal.pone.0021215.g003
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PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e21215Figure 4. Preparation of pRNA-AmiR chimerics. A) Schematic structure of cDNA encoding pRNA-AmiR chimerics or pRNA-Vector.
Sense, antisense AmiRs and the pRNA backbone were connected by poly-A linkers. The transcription of pRNA-AmiR chimerics was under the control
of a T7 phage 2.5 promoter. B) Phage 29 pRNA sequence and its secondary structure. The double stranded helical region marked by the box
would be replaced by the AmiRs sequences listed below to form pRNA-AmiR chimerics. C) Analysis of pRNA-AmiR chimeric transcripts. The
three chimeric pRNA-AmiRs and pRNA-Vec were analyzed by denaturing urea-PAGE. D) q-RT-PCR detection of mature AmiR. HeLa cells were
transfected with pRNA-AmiRs for 48 h and the expression levels of mature AmiR-1 and AmiR-2 were measured by q-RT-PCR using total RNAs and
normalized as described in Figure 3. The values shown represent the means 6 SD of the data from three independent experiments, P,0.05.
doi:10.1371/journal.pone.0021215.g004
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PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e21215Figure 5. Anti-CVB3 (Kandolf, high MOI) effect of pRNA-AmiR chimerics in HeLa cells. HeLa cells were transfected with different pRNA-
AmiRs or mock-transfected with Oligofectamine
TM only for 48 h and then infected with CVB3 (Kandolf, 10 MOI 8 h) or sham-infected with PBS. Cell
morphologies were analyzed by phase-contrast microscopy. Dying cells appeared rounding and detachment (A). Cell viability was measured by MTS assay
(B),the viral VP-1 proteinand caspase-3 cleavagewas detected by Western blot analysis (C, D)and viral particle formationwas measured by plaqueassay(E).
doi:10.1371/journal.pone.0021215.g005
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PLoS ONE | www.plosone.org 11 June 2011 | Volume 6 | Issue 6 | e21215Figure 6. Anti-CVB3 (Kandolf, low MOI) effect of pRNA-AmiR chimerics in HeLa cells. HeLa cells were transfected with different pRNA-
AmiRs or mock-transfected with Oligofectamine
TM only for 48 h and then infected with CVB3 (Kandolf, 0.01 MOI 20 h) or sham-infected with PBS. Cell
morphologies were analyzed by phase-contrast microscopy. Dying cells appeared rounding and detachment (A). Cell viability was measured by MTS
assay (B), the viral VP-1 protein was detected by Western blot analysis (C) and viral particle formation was measured by plaque assay (D).
doi:10.1371/journal.pone.0021215.g006
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PLoS ONE | www.plosone.org 12 June 2011 | Volume 6 | Issue 6 | e21215Figure 7. Anti-CVB3 (CG, low MOI) effect of pRNA-AmiR chimerics in HeLa cells. HeLa cells were transfected with different pRNA-AmiRs or
mock-transfected with Oligofectamine
TM only for 48 h and then infected with CVB3 (CG, 0.01 MOI 20 h) or sham-infected with PBS. Cell morphologies
were analyzed by phase-contrast microscopy. Dying cells appeared rounding and detachment (A). Cell viability was measured by MTS assay (B), the
viral VP-1 protein was detected by Western blot analysis (C) and viral particle formation was measured by plaque assay (D).
doi:10.1371/journal.pone.0021215.g007
Targeted Delivery of Anti-CVB3 Artificial MicroRNA
PLoS ONE | www.plosone.org 13 June 2011 | Volume 6 | Issue 6 | e21215targeting site of 39UTR in the target genes. The capability of the
designed AmiRs to tolerate mutations was further confirmed by
introducing mismatches in the 39UTR of CVB3, which highlight-
ed the advantage of AmiR therapy in RNAi-based viral inhibition
in terms of anti-mutation escape. To deliver the AmiR molecules
into the cells in a specific manner, we conjugated the AmiRs to a
Figure 8. Anti-CVB3 (Kandolf) effect of pRNA-AmiR chimerics in HL-1 cells. Cardiomyocyte HL-1 cells were transfected with different pRNA-
AmiRs or mock-transfected with Oligofectamine
TM only for 48 h and then infected with CVB3 (Kandolf, 10 MOI 20 h) or sham-infected with PBS. Cell
morphologies were analyzed by phase-contrast microscopy. Dying cells appeared rounding and detachment (A). Cell viability was measured by MTS
assay (B), the viral VP-1 protein was detected by Western blot analysis (C) and viral particle formation was measured by plaque assay (D).
doi:10.1371/journal.pone.0021215.g008
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PLoS ONE | www.plosone.org 14 June 2011 | Volume 6 | Issue 6 | e21215pRNA vector labeled with folate, which, to the best of our
knowledge, has not been tested for AmiR delivery. This F-pRNA-
Ab’(AmiR) chimerics was delivered to the target cells via the
interactions with the folate receptor, which is highly expressed in
cancer cells. This is the first report to demonstrate that miRNA-
like molecules can also be transported by pRNA conjugates and its
Figure 9. Anti-CVB3 (CG) effect of pRNA-AmiR chimerics in HL-1 cells. HL-1 cells were transfected with different pRNA-AmiRs or mock-
transfected with Oligofectamine
TM only for 48 h and then infected with CVB3 (CG, 10 MOI 20 h) or sham-infected with PBS. Cell morphologies were
analyzed by phase-contrast microscopy. Dying cells appeared rounding and detachment (A). Cell viability was measured by MTS assay (B), the viral
VP-1 protein was detected by Western blot analysis (C) and viral particle formation was measured by plaque assay (D).
doi:10.1371/journal.pone.0021215.g009
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PLoS ONE | www.plosone.org 15 June 2011 | Volume 6 | Issue 6 | e21215biological activity is preserved during delivery. This novel targeted
delivery system may be widely applicable to introduce other
natural or artificial miRNAs into cancer cells for cancer study and
treatment.
AmiR target location and anti-CVB3 effect
Depending on the target regions in 39UTR of CVB3 genome,
we observed strong inhibitory effects on viral replication by AmiR-
1 and AmiR-2, both of which target the big loop region (Y loop).
These two AmiRs significantly improved the cell viability during
CVB3 infection. No anti-CVB3 effect was found for AmiR-3
targeting the stem region of CVB3 39UTR, which indicates that
the secondary structures of the targeting sites play an important
role in affecting the targeting of AmiRs. The loop region with
more open spatial configurations may be easier for the AmiRs to
hybridize; while the stem region may not provide a convenient
access for AmiRs. Consistent with our results, previous studies also
suggested that the interactions between miRNAs and their targets
would be affected by the target structure, and the open loop
regions may be more accessible to the miRNA targeting [66,69].
This would provide important clues for the future designing of
anti-viral AmiRs.
Figure 10. Preparation of folate-labeled pRNA-AmiR monomers and heterodimers. A) Secondary structure of folate-labeled
chimeric pRNA-AmiR heterodimer. The 21-bp AmiR marked by a frame was covalently connected to a pRNA(A-b’)(nt 29–91) vector to form
pRNA-AmiR-1(A-b’). A pRNA(B-a’) vector was labeled with folate and dimerized with pRNA-AmiR (A-b’) by base-paring between the left- and right-
hand loops of the two monomers. B) Analysis of folate-labeled pRNA-AmiRs. The in vitro transcription products of folate (F)-labeled and non-
labeled pRNA-AmiRs were analyzed by denaturing urea-PAGE. C) Analysis of folate-labeled pRNA heterodimers. The folate labeled pRNA
vector (F-pRNA-Ba’) was dimerized with pRNA-AmiR. The dimerization products were analyzed by native PAGE. The dimers show a lower migration
speed than the monomers.
doi:10.1371/journal.pone.0021215.g010
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PLoS ONE | www.plosone.org 16 June 2011 | Volume 6 | Issue 6 | e21215Figure 11. Antiviral effect of AmiRs delivered by folate-labeled pRNA-AmiR monomers and heterodimers. HeLa cells were treated with
folate-labeled or non-labeled pRNA-AmiR monomers or heterodimers and infected with CVB3. The non-treated sample, F-pRNA-Ba’/pRNA-Ab’(AmiR-
S) treated cells and non-labeled pRNA-AmiR-1 treated sample were used as three controls. Cell morphology was observed under a phase contrast
microscope. Dying cells appeared rounding and detachment (A). Cell viability was also quantified by MTS assay (B). Anti-CVB3 effect was evaluated by
Western blot analysis of VP-1 protein (C) and viral plaque assay of CVB3 particles (D).
doi:10.1371/journal.pone.0021215.g011
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PLoS ONE | www.plosone.org 17 June 2011 | Volume 6 | Issue 6 | e21215Figure 12. Luciferase reporter assay to determine the specific targeting and the tolerance of AmiRs to mutations. A) Design of the
CVB3 39UTR mutants. Part of the CVB3 39UTR harboring the targeting sites of AmiR-1 and AmiR-2 was presented. Two mutants were designed by
substitution of nucleotides which are underlined. The numbers indicate the positions of the nts within the 39UTR of CVB3. B) Schematic diagram of
the pmir-GLO-CVB3-39UTR reporter construct. The CVB3 39UTR sequences (wt or mut) were inserted after the 39 end of firefly luciferase gene in
the pmir-GLO vector. C) Luciferase Assay of the targeting effect of pRNA-AmiR chimerics. HeLa cells were co-transfected with pRNA-AmiR
chimerics and luciferase reporter constructs containing wt or mutated CVB3 39UTR. The cells transfected only with a given reporter construct listed in
B) above served as a control in each specific group. Firefly and Renilla luciferase activities were detected using Dual-Glo luciferase analysis system
48 h after transfection. The ratio of luciferase activities (firefly/Renilla) was calculated and normalized to the one transfected only with empty pmir-
GLO vector.
doi:10.1371/journal.pone.0021215.g012
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PLoS ONE | www.plosone.org 18 June 2011 | Volume 6 | Issue 6 | e21215Figure 13. Detection of the IFN response in AmiR vector or pRNA-AmiR transfected HeLa cells. Total RNAs from HeLa cells transfected
with pRNA vector or pRNA-AmiR were isolated and reverse transcribed to cDNA. Q-RT-PCR was conducted to detect the expression level of IFN
response markers including IFITM1 (A), ISGF3-gamma (B), OAS1 (C) and OAS2 (D).
doi:10.1371/journal.pone.0021215.g013
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PLoS ONE | www.plosone.org 19 June 2011 | Volume 6 | Issue 6 | e21215Tolerance of siRNA and AmiR to viral genomic mutation
It has been reported that siRNAs may tolerate the mutations in
a certain extent but they have strong mismatch discriminations
[70]. The middle region of the siRNA is very sensitive to target
mutations while the 59 and 39 ends are relatively tolerable.
Previous studies in our laboratory using siRNA targeting CVB3
2A protease gene also found that the central region of siRNAs is
very sensitive to target mutation [10]. In our present study, the
designed AmiRs showed robust anti-viral effect with partial
complementation to the 39UTR of CVB3 genome. They are
tolerable to the mismatches in their middle and 39 region but not
the 59 region though the antiviral effect was slightly reduced due to
the mismatches (Fig. 12C). Previous studies on the targeting
principles of cellular miRNA have revealed that 59 seeding region
of miRNA is crucial for miRNA targeting and the complemen-
tation at the 39 region may be beneficial, but not always necessary,
for the specificity of miRNAs [30]. On the other hand, the
complementarity in the middle regions of miRNAs with its target
is related to the regulatory mechanism of miRNAs [30,60].
Mismatches between miRNAs and their targets in the middle
region may prevent the cleavage of the targets. However, most
endogenous and engineered miRNAs are still effective with
mismatches to their targets in the central region, indicating this
region is not as essential as the 59 or 39 end in terms of targeting
effect [30,60]. Other studies [5,13,14] and our data suggest that
AmiRs that mimic endogenous miRNAs probably use the same
mechanism of action. The mismatches in the central regions only
slightly reduced the targeting effect while the ones in the 59 seeding
region almost abolished the inhibitory function. Our results
provide further support that siRNA and miRNA are distinct from
each other in terms of mutation tolerance. This suggests that the
combination of siRNA and miRNA may prevent the viral escape
caused by mutations. In addition, the designed AmiR-1 and
AmiR-2 showed inhibitory effect on both Kandolf and CG strains
of CVB3. We further found that the AmiR-1 and AmiR-2
targeting sites are highly conserved in the genomes of various
CVB3 strains after bioinformatic analysis using DNAMAN
(Lynnon BioSoft). Seven of the 12 strains are exact the same
and the other 5 share fairly high homology in their 39UTRs
(Fig. 14). Thus, the designed AmiRs likely have a broad spectrum
of anti-CVB3 activity for various CVB3 strains.
Targeting of AS-ODN, siRNA and AmiR
Our previous studies designed AS-ODNs [39] and siRNAs [10]
targeting different regions of CVB3 genome to inhibit the viral
replication. By comparing these data with the present AmiR study,
we found that different anti-viral agents may tend to target
different regions of the viral genome. Our AS-ODNs were
designed to target either the 59 or 39UTR region of CVB3
genome and it seems that most of the effective ones were targeting
the 59UTR and only one AS-ODN targeting the end of the
39UTR was effective [39]; while for the siRNAs, almost all of the
effective ones were targeting the coding region but not the 59 or
39UTR [10]. In case of AmiRs, we designed three AmiRs
targeting the 39UTR and two of them demonstrated anti-CVB3
effect. Other studies using AmiRs targeting HIV-1 genomic RNA
showed that AmiRs targeting the 39UTR had stronger antiviral
activity than the one targeting the coding regions [5,13].
Another interesting point here is that even though targeting the
same site, AS-ODNs, siRNAs and AmiRs may achieve different
antiviral effects. One of the AS-ODNs designed to target nt 7342–
7361 in CVB3 39UTR showed no antiviral effect [39], while in the
present study, AmiR-2 targeting nearly the same site (nt 7342–
7362) exhibited inhibition on CVB3 replication. For targeting
within the 59UTR of CVB3, one of the AS-ODNs targeting nt
733–752 efficiently suppressed the CVB3 translation and replica-
tion [39]; while the designed siRNA targeting the same region (nt
733–751) showed little effect on CVB3 infection [10]. Although we
can not exclude the possibility that these differences were caused
by one nucleotide shift in the targeting sites, it seems more likely
that these three different types of pro-drugs may function through
distinct modes and thus showed different targeting effect in the
same targeting sites.
Specific delivery of AmiRs using pRNA to treat CVB3
infection
The pRNA vector is a novel system for delivery of therapeutic
molecules like siRNAs [42,45,46,47,48]. However, this strategy
has not been investigated on AmiRs. The replacement of the
helical region of pRNA with two complementary strands of
designed nucleotide sequences, like siRNA, does not influence its
folding and structure [55,71]. Although miRNA duplexes are
usually not totally base-paired as siRNA, the helical region of the
Figure 14. Comparison of AmiR-1 and AmiR-2 targeting sites in different CVB3 strains. CVB3 whole genome sequences were obtained
from Gene Bank and the regions targeted by AmiR-1 and AmiR-2 were compared using DNAMAN.
doi:10.1371/journal.pone.0021215.g014
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characteristics, it is also possible to replace the helical region of the
pRNA with miRNA duplex sequences for delivering miRNAs.
This study showed that the anti-CVB3 function of AmiRs was
preserved after covalently linking to a pRNA vector. The folate-
labeled pRNA-AmiR chimeric monomers, as well as heterodi-
mers, were then successfully delivered into HeLa cells via the folate
receptor and processed into functional, mature AmiRs. The
AmiRs delivered by this strategy also showed anti-CVB3 effect.
Thus our study is the first successful attempt to deliver miRNAs to
target cells using the pRNA vector.
The application of pRNA technology in treatment of CVB3
infection and viral myocarditis has several advantages. First, with
its nanoscale size, pRNA has lower immunogenicity than other
viral vectors [48,72]. Second, pRNA monomers possess the unique
capabilities to auto-assemble to dimmers, trimers and even
hexamers [47,48], which stabilizes the carried drugs and provides
the opportunities for simultaneous delivery of several therapeutic
agents as well as the specific ligands for targeted delivery [73]. In
addition, the drug delivery system using pRNA is protein free,
resulting in lower antibody-inducing activity that is essential for
repeated administration to treat chronic diseases like viral
myocarditis [74]. The previous attempts to deliver chemically
modified siRNA only last 15–45 min in the body and often trigger
undesired immune response [75,76]. After linking to pRNA
vector, the siRNA particles can achieve a half-life of 5–10 h with
little immune response or other toxicity observed in both in vitro
and in vivo administration [77].
However, there are still several challenges. The first one is to
increase the efficiency of delivery of pRNA-AmiR via ligand and
receptor interactions. This is based on the observation that pRNA-
AmiRs delivered by folate mediated internalization showed lower
anti-CVB3 effect than the one transfected by Oligofectamine
TM.
The second one is to search for other ligands such as RNA
aptamers, peptide or chemical ligands specific for the heart
delivery [78]. In this initial study, we used HeLa cells, a folate-
receptor positive cancer cell line and also a CVB3 susceptible host,
for treating CVB3 infection. For our final goal, we need to
discover new ligands to specifically deliver the drug to the heart to
treat CVB3 infection and viral myocarditis.
In conclusion, our designed AmiRs targeting the 39UTR of
CVB3 can inhibit viral replication and tolerate mutations in the
middle regions of target sites. This suggests the potential of AmiRs
to reduce drug resistance caused by viral escape mutations and the
promise to deliver AmiRs using folate-conjugated pRNA vectors
linked with a specific ligand. This strategy may be further
developed as a system for RNAi-based drug design and delivery.
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